Immunization News and Research

RSS

Special issue delves into global polio eradication efforts and modeling

Launched in 1988, the Global Polio Eradication Initiative (GPEI) stands out as one of the largest, internationally coordinated global public health major projects conducted to date, with cumulative spending of over $16.5 billion for 1988-2018, according to the World Health Organization.

16 Feb 2021

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

In the study, published on the preprint server bioRxiv, the team evaluated the ability of AS03, CpG 1018 formulated in Alum, the TLR-7 agonist adsorbed to Alum (AS37), the squalene-in-water emulsion (O/W), and Alum to boost protective immunity against SARS-CoV-2.

15 Feb 2021

Can Pfizer and Moderna end the pandemic by sharing their vaccine designs? It’s not that simple

Vaccine makers Pfizer and Moderna earned praise for creating highly effective covid-19 vaccines in record time.

15 Feb 2021

New study shares preliminary data on Pfizer vaccine’s effectiveness in Israel

Researchers have shown that by mid-January, the number of COVID-19 cases and hospitalizations in Israel began to decline with a larger and earlier decrease among older people.

11 Feb 2021

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Researchers at the Polish Academy of Sciences in Warsaw have identified a substrain of the recently emerged B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may confer resistance to antibody neutralization.

10 Feb 2021

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Researchers in the United States and Canada have conducted a study showing that just a single dose of either the Pfizer-BioNTech or Moderna vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is likely to protect against emerging variants.

9 Feb 2021

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Researchers at NYU Grossman School of Medicine in New York have conducted a study demonstrating the effectiveness of the Pfizer-BioNtech BNT162b2 vaccine against recently emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Feb 2021

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Researchers in China have developed three SARS-CoV-2 nanoparticle vaccines, containing receptor-binding domain (RBD) trimer, S1 trimer, and ectodomain (ECD) trimer, respectively. To do this, they have used Ferritin nanoparticle self-assembly technology.

9 Feb 2021

Scalise’s claim that unauthorized immigrants are getting priority for vaccination misses the point

During a Feb. 2 interview on Fox News, Rep. Steve Scalise (R-La.) claimed President Joe Biden was allowing unauthorized immigrants to move ahead of American citizens to get their covid-19 vaccines.

9 Feb 2021

COVID-19 vaccination associated with 3- to 5-fold reduction in viral load

Researchers in Israel report a reduction in viral load in vaccinated individuals.

9 Feb 2021

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

A new study describes the first case of anti-SARS-CoV-2 antibodies detected in the cord blood of an infant born to a mother immunized with the first dose of an mRNA COVID-19 vaccine three weeks earlier.

9 Feb 2021

4th preclinical study for Novavax in non-human primates, tests SARS-CoV-2 variants

Researchers in the United States have identified specific immune correlates that might be key to ensuring that vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protects against not only disease, but also viral transmission and emerging variants.

8 Feb 2021

The state of vaccine supply: ‘Opaque.’ Unpredictable. ‘Hard to pin down.’

Even as the pace of vaccination against covid-19 has steadily accelerated — hitting an average of 1.3 million doses a day in the last days of January — the frustration felt by many of those unable to secure an appointment hasn't waned.

5 Feb 2021

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

A team of scientists from India has recently tested the efficacy and immunogenicity of two different concentrations of a plasmid DNA-based vaccine candidate ZyCoV-D. The findings reveal that the vaccine candidate administered via Needle Free Injection System (NFIS) can significantly induce the production of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG and neutralizing antibodies for a prolonged period.

4 Feb 2021

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

Researchers in China have reported phase I/II clinical trial findings showing that the vaccine candidate CoronaVac is well tolerated among older individuals and effectively generates antibody responses against severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2) - the agent that causes coronavirus disease 2019 (COVID-19).

4 Feb 2021

New study supports UK’s delay of the SARS-CoV-2 Pfizer vaccine second dose

After reanalyzing data from 500,000 people in Israel who received the Pfizer vaccine, researchers suggest a single dose provides sufficient immunity after about 21 days, thus providing support for the UK’s decision to delay the second dose to 12 weeks.

4 Feb 2021

Immunization News and Research

Special issue delves into global polio eradication efforts and modeling

Nanoparticle COVID-19 vaccine stimulates robust and long lasting immunity in primates

Can Pfizer and Moderna end the pandemic by sharing their vaccine designs? It’s not that simple

New study shares preliminary data on Pfizer vaccine’s effectiveness in Israel

Substrain of SARS-CoV-2 variant in UK may resist antibody neutralization

Both mRNA vaccines protect against emerging variants of SARS-CoV-2

Pfizer-BioNTech COVID-19 vaccine effective against variants, study shows

Researchers develop self-assembling nanoparticle SARS-CoV-2 vaccines

Scalise’s claim that unauthorized immigrants are getting priority for vaccination misses the point

COVID-19 vaccination associated with 3- to 5-fold reduction in viral load

Vaccinated mothers may pass on SARS-CoV-2 antibodies to newborns

4th preclinical study for Novavax in non-human primates, tests SARS-CoV-2 variants

The state of vaccine supply: ‘Opaque.’ Unpredictable. ‘Hard to pin down.’

ZyCoV-D SARS-CoV-2 DNA vaccine shows robust immunogenicity and protective efficacy in Rhesus macaquesys

Phase I/II trial findings support use of CoronaVac vaccine in older individuals

New study supports UK’s delay of the SARS-CoV-2 Pfizer vaccine second dose

Pfizer vaccine and Eli Lilly monoclonal antibodies successfully neutralize SARS-CoV-2 UK variant, finds study

Researchers develop prototype COVID-19 vaccine using DNA vaccine platform

100 million covid shots in 100 days doesn’t get us back to normal

Two-dose regimen of adenovirus-based vaccine offers 91.6% efficacy against COVID-19

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News